19 July 2019 - BEAM Alliance

BEAM Alliance: Time to give your feedback on how to characterize antimicrobial activity!

The BEAM Alliance proposed a six-way approach to characterize ATM activity, with the aim of opening new doors in the…

12 April 2019 - BEAM Alliance

BEAM Alliance is proposing a new approach to foster better differentiation between antimicrobials: ‘A new vision for AMR innovation to support medical care’!

By linking a specific ATM to a specific step of the infectious process, novel clinical outcomes could be identified that…

25 March 2019 - BEAM Alliance

BEAM Alliance is releasing a new position paper on PUSH Incentives: ‘Supporting financial investments on R&D to de-risk antimicrobial development!’

The intention of this Memo is to provide different suggestions to help ensure that the R&D funding instruments (e.g. from…

BEAM News
Member News
Events

Latest news of BEAM Alliance

19 July 2019 - BEAM Alliance

BEAM Alliance: Time to give your feedback on how to characterize antimicrobial activity!

The BEAM Alliance proposed a six-way approach to characterize ATM activity, with the aim of opening new doors in the…

06 June 2019 - BEAM Alliance

Emergency on planet AMR: a vital pipeline to protect

The sooner we come up with practical solutions, the more SMEs (and currently developed products) we can save from vanishing.…

12 April 2019 - BEAM Alliance

BEAM Alliance is proposing a new approach to foster better differentiation between antimicrobials: ‘A new vision for AMR innovation to support medical care’!

By linking a specific ATM to a specific step of the infectious process, novel clinical outcomes could be identified that…

25 March 2019 - BEAM Alliance

BEAM Alliance is releasing a new position paper on PUSH Incentives: ‘Supporting financial investments on R&D to de-risk antimicrobial development!’

The intention of this Memo is to provide different suggestions to help ensure that the R&D funding instruments (e.g. from…

24 September 2018 - BEAM Alliance

Antibiorésistance : BEAM Alliance tire la sonnette d’alarme

Priorités : Alerter les pouvoirs publics sur le besoin médical et l’urgence associés à la pénurie de nouveaux traitements contre…

07 June 2018 - BEAM Alliance

BEAM writes to Representatives of the US congress to support The Pandemic and All Hazards Preparedeness Act (PAHPA) currently discussed at the House of Representatives.

BEAM writes to Representatives of the US congress to support The Pandemic and All Hazards Preparedeness Act (PAHPA) currently discussed…

page 1/3

Tweets by alliancebeam

View twitter feed

Latest news of BEAM Members

17 July 2019 - Polyphor Ltd

Polyphor closes the Phase III PRISM studies of murepavadin intravenous formulation and evaluates further product improvement options

“We would like to thank the patients, the investigators and all the scientists involved for their contribution to the development…

16 July 2019 - Pherecydes Pharma

Pherecydes Pharma and BIOASTER join forces to explore the use of phage therapy to treat complicated urinary tract infections

“This project will be an important step forward for phage therapy and a new hope for patients,” commented Guy-Charles Fanneau…

15 July 2019 - Motif Bio plc

Motif Bio Submits Meeting Request and Package to the U.S. FDA for Iclaprim

Graham Lumsden, Chief Executive Officer, said: “As we take this next step towards potential regulatory approval for iclaprim in the…

03 July 2019 - Da Volterra

Da Volterra Announces Completion of Patient Recruitment for its Phase 2 Clinical Study with DAV132, a Novel Microbiota Protective Therapy

“We are pleased to announce the completion of recruitment for our first-in-patient Phase 2 study for our innovative and most…

03 July 2019 - Nosopharm

Nosopharm and Evotec enter into collaboration to accelerate development of novel antibiotics

NOSO-502 is the first clinical candidate in the novel antibiotic class called Odilhorhabdins (ODLs). It inhibits the bacterial ribosome with…

27 June 2019 - PhagoMed Biopharma GmbH

Investors Support Phage Therapy; Novel Approach to Solve The Antibiotics Crisis Receives Further Millions

PhagoMed Biopharma GmbH (PhagoMed) works on solutions for the global antibiotics crisis – the increasing rate of multi-drug resistances against…

page 1/15

Events

13 November 2019

Matchmaking Symposium ‘Emerging Antimicrobials and Diagnostics in AMR 2019’

The event provides an excellent podium for emerging Antimicrobials and Diagnostics as well as an exciting program including orchestrated matchmakings,…

11 November 2019

BIO-Europe, 25th Annual International Partnering Conference

Celebrating 25 years of facilitating partnerships that drive life science dealmaking!

19 October 2019

4th International Course on Antibiotics and Resistance (ICARe)

The emergence and spread of bacteria resistant to many drug classes seriously threaten all branches of modern medicine. There is…

02 October 2019

IDWeek 2019

IDWeek is the joint annual meeting of the Infectious Diseases Society of America (IDSA), Society for Healthcare Epidemiology of America…

25 September 2019

Phage Futures Europe

Translating phage-based applications into clinically and commercially viable therapeutics

06 September 2019

CeBIL Annual Symposium 2019: Legal Innovation to Support the Development of Antimicrobial Drugs

This symposium will explore the complex interactions between law and antimicrobial research and development. Advancing our understanding of this ecosystem…

03 September 2019

ASM/ESCMID Conference on Drug Development to Meet the Challenge of Antimicrobial Resistance

Antimicrobial drug resistance (AMR) is an urgent global health problem. New antimicrobial drug development is increasingly viewed as a priority…

20 August 2019

REVIVE webinar: Models for antimicrobial R&D: Computational modelling for population PK and PKPD

In this webinar, Lena Friberg and Elisabet Nielsen (Department of Pharmaceutical Biosciences, Uppsala University, Sweden), will discuss: - Population PK…

16 July 2019

OBN BioTuesday: What’s New in Antimicrobial Resistance – is there light at the end of the tunnel?

The development of resistance to antimicrobials threatens to reverse the changes in public health that have occurred over the last…

page 1/3